ViaOpta Nav for iPhone by Novartis Now on Apple Watch. Yes, but... There's only one problem... Read more »
Longtime readers might recall that every so often I hit on the topic of the "dark matter" of drug target space. We have a lot of agents that hit G-protein coupled receptor proteins, and plenty that inhibit enzymes. Those, though, are...Show More Summary
Good morning, everyone, and how are you today? A spot of rain is descending on the Pharmalot campus, but our spirits remain as sunny as ever. As you may recall us noting previously, the Morning Mayor used to say that 'every brand new...Show More Summary
A union that represents hotel workers has started a campaign to end pharmaceutical industry funding of continuing medical education.
The U.S. Department of Justice says that Novartis should pay up to $3.35 billion in damages and civil fines for using kickbacks to boost sales of two drugs that caused federal health care programs to overpay for medicines.
Celgene placed a big bet on a hot therapy that harnesses the immune system to fight cancer, by striking a deal with Juno Therapeutics, but the deal was greeted with a mix of enthusiasm and skepticism.
Rise and shine, another busy day is on the way. A long-holiday weekend may be looming on this side of the pond, but we remain as engaged as ever in sorting out a never-ending stream of events. Of course, a few cups of stimulation make the task much easier. Show More Summary
When you look at the stock charts of the major pharma companies, there's not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%, and most of the big drug stocks are actually negative (Merck -0.4%, Sanofi down 6%, J&J down 7%, AstraZeneca down 13%). Show More Summary
Summer vacation is here! Before you launch your July 4 festivities, please enjoy these Drug Channels fireworks: The valuation behind Diplomat’s acquisition of Burman’s specialty pharmacy A Wall Street perspective on the CVS-Target deal The outlook for drugstore chains Plus, we revisit a stirring patriotic message from Sam the Eagle. Show More Summary
25% More People Think They Have PBA After Seeing Danny Glover Laughing Uncontrollably! See how "The Most Interesting Pharma Guy in the World" reacted to the PBA Assessment... Read more »
Eli Lilly was fined $11 million by Brazilian authorities for pursuing “sham” patent litigation that was designed to extend exclusivity for its Gemzar cancer treatment.
Don't believe me? Read more »
A pair of public health advocacy organizations has filed a lawsuit against the FDA, claiming the agency failed to release clinical trial data for Gilead Sciences’ hepatitis C treatments on a timely basis.
A reader sent along this link to an article at the New York Review of Books on the relentless emphasis on STEM jobs. The viewpoint of its author, Andrew Hacker, was preordained: he's a political scientist who started a controversy about...Show More Summary
Hello, everyone, and welcome to another working week, although this will be a short one on this side of the pond, due to the upcoming holiday. We are celebrating early, in fact, thanks to a bright, shiny sun and cool breeze to go with our ritual cup of stimulation. Show More Summary
Bruce Booth has a long post on external R&D in biopharma. He's mostly talking about some of the newer ways to do that, rather than traditional deals and outsourcing. These include larger companies partnering with VC firms to launch smaller ones, large investments in the smaller players with specific rights to buy some of the successes, etc. Show More Summary
A closely watched legal battle on off-patent uses of prescription drugs is slated to come to trial in London on Monday.